ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pomalidomide

Also written as “Pomalidomide”, “Pomalidomide 4 MG Oral Capsule” and “Xetrane® (Pomalidomide) 4 mg Hard Capsule”.

Its studies are mostly in Multiple Myeloma · Primary Myelofibrosis · Brain Neoplasms · Scleroderma, Systemic · Hematologic Neoplasms, led by 8 companies.

Drug pagePomalidomide: every studyMany companies study it; this page follows only the 37 they lead. All 160 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 15, 201037 company-led studies, 2 open or runningNext primary completion: Jan 10, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb251 open or runningphase 3since Jul 15, 2010Nov 7, 2003Jan 10, 2027phase 3 · NCT05519085
Oncotherapeuticsits history only40 open or runningphase 2since Feb 20, 2012Feb 20, 2012none ahead
Amgenits history only20 open or runningphase 2since Nov 22, 2019Oct 18, 2016none ahead
Simcere Pharmaceutical Groupits history only20 open or runningphase 3since Sep 24, 2016Sep 24, 2016none ahead
Criteriumits history only10 open or runningphase 2since Oct 19, 2011Oct 19, 2011none ahead
Knight Therapeutics (USA)its history only10 open or runningphase 1since Jul 3, 2026Jul 3, 2026none ahead
Megalabsits history only11 open or runningphase 1since Sep 15, 2023Sep 15, 2023none ahead
Takedaits history only10 open or runningphase 4since Dec 20, 2021Dec 20, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Nov 7, 2003.

  1. Jan 27, 2012Phase 1 study in Anemia, Sickle CellNCT01522547 · 12 enrolled · United States
  2. Mar 19, 2012Phase 2 study in Scleroderma, SystemicNCT01559129 · 23 enrolled · United States, Australia, France and more
  3. Mar 29, 2012Phase 1 study in Multiple MyelomaNCT01568294 · 12 enrolled · Japan
  4. Oct 12, 2012Phase 1 study in Pharmacology, ClinicalNCT01707407 · 32 enrolled · United States
  5. Oct 22, 2012Phase 3 study in Multiple MyelomaNCT01712789 · 682 enrolled · Austria, Belgium, Denmark and more
  6. Nov 23, 2012Phase 3 study in Multiple MyelomaNCT01734928 · 559 enrolled · United States, Austria, Canada and more
  7. Apr 17, 2013Phase 1 study in Liver DiseasesNCT01835561 · 32 enrolled · United States
  8. Sep 17, 2013Phase 2 study in Multiple MyelomaNCT01946477 · 186 enrolled · United States, Canada, Japan and more
  9. Nov 12, 2013Phase 1 study in Clinical Pharmacology, Healthy Volunteer StudyNCT01986894 · 72 enrolled · United States
  10. Dec 10, 20132 phase 2 studies in Multiple MyelomaNCT02011113, NCT02045017
  11. Jun 18, 2014Phase 1 study in Healthy VolunteersNCT02168205 · 55 enrolled · United States
  12. Aug 18, 2017Phase 2 study in Central Nervous System NeoplasmsNCT03257631 · 53 enrolled · United States, France, Italy and more
  13. Aug 16, 2018Phase 3 study in Multiple MyelomaNCT03651128 · 386 enrolled · United States, Belgium, Canada and more
  14. Aug 25, 2022Phase 3 study in RecurrenceNCT05519085 · 810 planned · United States, Argentina, Australia and more

Ahead

  1. Jan 10, 2027Primary completion: phase 3 study in RecurrenceNCT05519085

TargetBeta

“CRL4(CRBN) E3 ubiquitin ligase inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109

Studies

All 25 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05519085Recurrence · United States, Argentina, Australia and more3RecruitingJan 10, 2027810
NCT03651128Multiple Myeloma · United States, Belgium, Canada and more3CompletedApr 13, 2026386
NCT03257631Central Nervous System Neoplasms · United States, France, Italy and more2CompletedSep 14, 202353
NCT02168205Healthy Volunteers · United States1CompletedSep 19, 201455
NCT02045017Multiple Myeloma · Austria, France, Germany and more2CompletedJan 27, 201781
NCT02011113Multiple Myeloma · Japan2CompletedSep 201436
NCT01986894Clinical Pharmacology, Healthy Volunteer Study · United States1CompletedDec 2, 201372
NCT01946477Multiple Myeloma · United States, Canada, Japan and more2CompletedApr 30, 2025186
NCT01835561Liver Diseases · United States1CompletedAug 16, 201432
NCT01734928Multiple Myeloma · United States, Austria, Canada and more3CompletedMay 9, 2022559
NCT01712789Multiple Myeloma · Austria, Belgium, Denmark and more3CompletedDec 11, 2019682
NCT01707407Pharmacology, Clinical · United States1CompletedNov 1, 201232
NCT01568294Multiple Myeloma · Japan1CompletedJul 8, 201512
NCT01559129Scleroderma, Systemic · United States, Australia, France and more2TerminatedNov 3, 201623
NCT01522547Anemia, Sickle Cell · United States1CompletedOct 1, 201212
NCT01497093Multiple Myeloma · United States1CompletedJul 23, 201934
NCT01474330Healthy · United States1CompletedOct 1, 201133
NCT01324947Multiple Myeloma · Australia, Belgium, Canada and more3CompletedJul 31, 201474
NCT01311687Multiple Myeloma · United States, Australia, Belgium and more3CompletedMar 1, 2013455
NCT01178281Primary Myelofibrosis · United States, Australia, Austria and more3CompletedJan 1, 2013267
NCT00833833Multiple Myeloma · United States, Canada2CompletedApr 2011259
NCT00717522Sarcoma · United States2TerminatedJan 1, 20097
NCT00537511Carcinoma, Small Cell · United States, Canada2TerminatedNov 1, 201022
NCT00463385Primary Myelofibrosis · United States, Austria, Italy and more2CompletedMay 1, 200988
NCT00072722Prostatic Neoplasms · United States2Completed36

How it is read

Names in the registry

  • “Pomalidomide”, 41 entries
  • “pomalidomide”, 4 entries
  • “Pomalidomide 4 MG Oral Capsule”, 2 entries
  • “Xetrane® (Pomalidomide) 4 mg Hard Capsule”, 1 entry
  • “Imnovid® (Pomalidomide) 4 mg Hard Capsule”, 1 entry

Codes read as this program: CC4047.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.